https://prabadinews.com/
administrator

Many Patients With Statin Intolerance Self-Medicate, Despite No Link to Lowering LDL-C

Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms…

Therapeutic Response with Genialis – Life Sciences Today Podcast Episode 24

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest…

FluMist Home Delivery Expands Access to Seasonal Influenza Vaccination

FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US…

The Role of LAIs in Schizophrenia: Convenience, Adherence, and Access

Explore the benefits and challenges of long-acting injectables (LAIs) in managing schizophrenia for improved patient outcomes.

Iza-Bren Receives FDA Breakthrough Therapy Designation for EGFR-Mutated NSCLC

The action is supported by 3 ongoing clinical trials, which are evaluating izalontamab brengitecan (iza-bren) in non–small cell lung cancer…

Beyond the Buzz: Digital Health Needs a Reality Check—And That’s a Good Thing

The following is a guest article by Julien de Salaberry, CEO at Galen Growth For much of the past decade,…

Ice Cream Factory Issues Allergy Alert on Undeclared Almond in Vanilla G.Nutt Ice Cream

Ice Cream Factory of Mount Vernon, NY is recalling 40 Pints, 8 Quarts and 3 Half Gallons of Vanilla G.Nutt…

Study: Apitegromab Meaningfully Improves Motor Function in Spinal Muscular Atrophy

Results from the phase 3 SAPPHIRE trial show significant improvements in motor function in children and adults with spinal muscular…

Supreme Group Acquires Pivot Design, Marking a Significant Expansion in Pharma and Rare Disease

Ninth Acquisition in 18 Months Adds Brand, Creative, and Omnichannel Strength to Supreme Group’s Rapidly Growing Healthcare and Life Sciences…

Rising 340B Costs Drive Employer Spending and Spark Calls for Reform

Employers are facing higher costs and employees higher premiums as 340B’s growth drives lost rebates and rising drug prices.